Mariana Oncology’s Post

Agree with Michael. It is just the beginning for #Theranostics 😃 Society of Nuclear Medicine and Molecular Imaging (SNMMI) #NuclearMedicine #SNMMI #Theranostics #MichaelHofman #SaulHertz #ProstateCancer #PSMAPET #ClinicalTrials #MedicalImaging #LuPSMA #Terbium161

The results of multicenter studies on PSMA treatment with Terbium-161 (¹⁶¹Tb) continue to emerge in Turkey. Prof. Dr. F. Gül Gümüşer, Head of the Department of Nuclear Medicine at Manisa Celal Bayar University, shared data from a treatment applied to an 84-year-old prostate cancer patient. As part of the study, imaging results from the 4th and 24th hours of the treatment process were presented. These findings represent an important starting point for Terbium-161 research in Turkey. The initial results from multicenter studies indicate promising progress. Yasemin Parlak Ceren Sezgin TerThera b.v. #ManisaCelalBayarÜniversitesiHafsaSultanHastanesi #AnkaraÜniversitesiCebeciTıpFakültesi #İstanbulÜniversitesiİstanbulTıpFakültesi #AnkaraBilkentŞehirHastanesi #AnadoluSağlıkMerkezi #YeditepeÜniversitesiHastaneleri #MedicalParkHastanelerGrubu #edhnuclear #prostatecancer #tb161

Nuclear Medicine Abstracts session on Day 2 of the RANZCR ASM! 📒 Talks for this session include; Differentiating the normal from abnormal: 68Ga-DOTATATE PET by Dr Dhruvil Oza Correlating PET-CT with Circulating Tumour Cell Detection to Predict Treatment Responses in Head and Neck Cancer by Dr Michael Wong Predictive Value of Pre-infusion FDG PET/CT Parameters for Clinical Outcomes and Toxicities in Relapsed/Refractory BCell -Lymphoma following CAR T-cell Therapy by Dr Sweeka Alexander Variations of Gallium(67Ga)-Citrate uptake in allograft kidneys on planar scintigraphy by Dr Julia Skelton #RANZCR2024 #ClinicalRadiology #NuclearMedicine

I just watched an incredible lecture by Michael Hofman from the Peter MacCallum Cancer Centre at SNMMI. He was awarded the prestigious Saul Hertz Prize in theranostics. Saul Hertz pioneered radioisotope therapy, asking, “Can we create radioactive iodine artificially?” His work revolutionized the field. Hofman, initially in nuclear cardiology, shifted to PET/CT with Gallium-68 tracers. Realizing the need for strong clinical trial data, he established a collaborative network in Australia, advancing nuclear medicine worldwide. His PROPSMA study showed PSMA PET/CT is 40% superior to conventional imaging for prostate cancer, leading to its inclusion in global guidelines and making it one of the top-cited papers in Lancet Oncology. He emphasized the need for high-quality clinical trials to transform nuclear medicine. The TheraP study compared Lutetium-PSMA with cabazitaxel, showing better response and fewer side effects. Hofman also highlighted the exciting potential of Terbium-161 PSMA in the Violet study. Stay tuned for some standout slides from his lecture! Society of Nuclear Medicine and Molecular Imaging (SNMMI) #NuclearMedicine #SNMMI #Theranostics #MichaelHofman #SaulHertz #ProstateCancer #PSMAPET #ClinicalTrials #MedicalImaging #LuPSMA #Terbium161

This article highlights the effectiveness of Lutetium-177, Actinium-225, and Yttrium-90 in treating cancers, detailing their benefits and manageable side effects. These advanced nuclear medicine therapies offer significant tumor control, improved survival, and enhanced quality of life for patients. Read the full article: https://lnkd.in/dg98Cuir #Nuclearmedicinetherapy #Lutetium177therapysideeffects #Actinium225 #Yttrium90 #PRRT #nuclearmedicine #Bonemarrowsuppressioninnuclearmedicine #RenaltoxicityinLutetium177therapy #Fatiguefromnuclearmedicinetreatments #HematologicaltoxicityinActinium225therapy #GastrointestinalsideeffectsofY90 #Radiation #cancertherapy #Longtermeffectsof #nuclearmedicine #Preventingsideeffectsincancer #radiationtherapy #Nauseaandvomitinginnuclearmedicine #Kidneydamageriskinnuclearmedicinetreatments

New Data on Terbium-161 (¹⁶¹Tb) PSMA Treatment Studies in Turkey The outcomes of multicenter studies on Terbium-161 (¹⁶¹Tb) PSMA treatment in Turkey continue to emerge, marking significant progress in nuclear medicine. Prof. Dr. Kezban Berberoglu, Director of the Nuclear Medicine Department at Anadolu Medical Center Hospital, recently shared findings from a treatment applied to a 53-year-old prostate cancer patient. This latest update includes imaging results from the 120th hour of the treatment process, offering deeper insights into the therapeutic potential of Terbium-161. These findings represent an essential milestone for Terbium-161 research in Turkey and reinforce the promising progress reflected in the initial results of multicenter studies. We look forward to seeing how these advancements shape the future of prostate cancer treatment. TerThera b.v. Abdullah Birak #ManisaCelalBayarÜniversitesiHafsaSultanHastanesi #AnkaraÜniversitesiCebeciTıpFakültesi #İstanbulÜniversitesiİstanbulTıpFakültesi #AnkaraBilkentŞehirHastanesi #AnadoluSağlıkMerkezi #YeditepeÜniversitesiHastaneleri #MedicalParkHastanelerGrubu #tb161 #Terbium161 #PSMATreatment #ProstateCancer #NuclearMedicine #EDHNuclear

👉 Still about the Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), that happened last June 2024, in Toronto. Happy to share that our submitted abstract received the Best International Abstract Award at the SNMMI 2024 Conference!! Thanks to SNMMI Committee for the award!! Thanks to our Nuclear Medicine-Radiopharmacology team at Champalimaud Foundation, specially to Francisco Oliveira, Joana Castanheira and Professor Durval Costa. 📚 This work evaluated the clinical impact of deep-learning-based segmentation for tumor quantification in FDG PET/CT images, with application for lung, melanoma and lymphoma patients. Find out more: https://lnkd.in/dRqbBN6E #SNMMI #nuclearmedicine #artificialintelligence

The wonders of Theranostics is beyond what our conventional medicine could elucidate. Below is the result of an advanced and extensive prostate cancer patient before and after Radionuclide (LuPSMA) therapy. This is obviously beyond Chemo and Radiation Therapy. When medicine fail, Nuclear Medicine will surely intervene. It's a good time to be alive💃💃 #nuclearmedicine #theranostics #radionuclides #radiochemistry #PETCT

Results from the multicenter study on Terbium-161 PSMA treatment in Türkiye continue to emerge. Prof. Dr. Elif Özdemir, the Administrative Head of the Nuclear Medicine Clinic at Bilkent City Hospital, shared data from a treatment applied to a 73-year-old prostate cancer patient. This study, led by Principal Investigator Prof. Dr. Nuriye Ozlem Kucuk, includes observations of developments in the treatment process and changes in PSA levels. These findings represent an important starting point for Terbium-161 research in Türkiye. The initial results from multicenter studies indicate promising progress. We will continue to support innovative solutions in healthcare and develop patient-centered treatments. TerThera b.v. #AnkaraÜniversitesiCebeciTıpFakültesi #ManisaCelalBayarÜniversitesiHafsaSultanHastanesi #İstanbulÜniversitesiİstanbulTıpFakültesi #AnkaraBilkentŞehirHastanesi #AnadoluSağlıkMerkezi #YeditepeÜniversitesiHastaneleri #MedicalParkHastanelerGrubu #edhnuclear #prostatecancer #tb161 Nazım Coşkun

Check this out to learn about how Nuclear Medicine helps with the fight against cancer.